A commercial-scale gene therapy platform needs to couple high production processes with effective and streamlined downstream purification methods. At Catalent, our gene therapy team is critically focused on the need for your development process to be truly commercial-ready. Through calculated planning of potential future-proof and early design of process/analytical development and characterization together with manufacturing-scale bioproduction methods, our team offers you not just secure premier capacity but also the ability to potentially reduce the probability of late-stage challenges.
Our scientists, engineers, quality experts, manufacturing operators, and project managers are closely connected with your project from start to finish. Whether it is evaluating new production technology like the iCELLis® Bioreactor Systems for early process optimization and robust titers or optimizing your stability studies in advance of critical need, we are committed to making your transition to commercial launch as seamless as possible.
iCELLis is a trademark of Pall Corporation.